The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Condition:   Parkinson Disease Psychosis
Intervention:   Other: Real-world, non-interventional
Sponsor:   ACADIA Pharmaceuticals Inc.
Recruiting - verified May 2017

A Study of MP-101 in the Treatment of Psychosis in Alzheimer's Disease

Conditions:   Psychosis;   Alzheimer Disease
Interventions:   Drug: MP-101;   Drug: Placebo
Sponsor:   Mediti Pharma Inc.
Recruiting - verified May 2017

Is Cognitive Training Neuroprotective in Early Psychosis?

Conditions:   Psychosis;   Healthy
Interventions:   Device: Magnetic Resonance Imaging;   Behavioral: Treatment as Usual;   Behavioral: Targeted Cognitive Training;   Other: Healthy Controls
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Institutes of Health (NIH)
Not yet recruiting - verified April 2017

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Condition:   Parkinson Disease Psychosis
Interventions:   Drug: SEP-363856;   Drug: Placebo capsule
Sponsor:   Sunovion
Recruiting - verified May 2017

Reducing the Duration of Untreated Psychosis

Condition:   First Episode Psychosis
Intervention:   Other: Community Campaign La CLAVE
Sponsors:   University of Southern California;   University of California, Los Angeles;   National Institute of Mental Health (NIMH)
Recruiting - verified March 2017

COllaborative Shared Care to IMprove Psychosis Outcome

Condition:   Psychosis
Intervention:   Behavioral: Collaborative shared care
Sponsor:   University of Ibadan
Recruiting - verified September 2016

Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement

Condition:   Psychotic Disorders
Interventions:   Other: Electronic Screen + Education (Phase 1);   Other: Targeted Provider Education (Phase 1);   Other: Community Mobile Engagement (Phase 2);   Other: Clinic based Engagement (Phase 2)
Sponsor:   University of California, Davis
Recruiting - verified July 2016

Striatal Connectivity and Clinical Outcome in Psychosis

Condition:   Psychotic Disorders
Intervention:   Drug: Risperidone (patients only)
Sponsors:   Northwell Health;   National Institutes of Health (NIH)
Recruiting - verified March 2017

Expanded Access of Pimavanserin for Patients With PD Psychosis

Condition:   Parkinson's Disease Psychosis
Intervention:   Drug: Pimavanserin tartrate
Sponsor:   ACADIA Pharmaceuticals Inc.
Approved for marketing - verified April 2017

Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe

Condition:   Ultra High Risk for Psychosis
Interventions:   Drug: Omega-3 fatty acids;   Other: Placebo
Sponsor:   Rene Kahn
Recruiting - verified May 2017

Gabapentin in Patients at Clinical Risk for Psychosis

Condition:   Clinical High Risk for Psychosis
Interventions:   Drug: Gabapentin;   Drug: Placebo
Sponsor:   New York State Psychiatric Institute
Recruiting - verified December 2016

CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes

Conditions:   Insomnia;   Psychosis
Interventions:   Behavioral: Cognitive Behavioral Therapy-Insomnia;   Behavioral: Health and Wellness
Sponsors:   VA Office of Research and Development;   VA Maryland Health Care System
Not yet recruiting - verified March 2017

Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis

Condition:   Psychosis
Interventions:   Behavioral: CLUES;   Behavioral: therapy and computer games
Sponsors:   Beth Israel Deaconess Medical Center;   National Institute of Mental Health (NIMH)
Recruiting - verified March 2017

A Study of the Effectiveness of Cognitive Adaptation Training in Early Intervention for Psychosis

Condition:   Psychosis
Interventions:   Behavioral: Cognitive Adaptation Training;   Behavioral: Action Based Cognitive Remediation
Sponsor:   Centre for Addiction and Mental Health
Recruiting - verified December 2016

The BC Psychosis Program Biobank and Database for Genetic Polymorphisms and Their Associations With Psychosis Disorder

Conditions:   Psychosis;   Schizophrenia
Intervention:   Genetic: Blood samples for whole genomic/transcriptomic sequencing
Sponsors:   University of British Columbia;   Vancouver Coastal Health
Recruiting - verified May 2016

Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis

Conditions:   Social Phobia;   Psychosis
Interventions:   Behavioral: Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis;   Behavioral: Group Computer assisted cognitive remediation therapy
Sponsors:   McGill University;   Canadian Institutes of Health Research (CIHR)
Recruiting - verified May 2017

Cognitive Behavioral Social Skills Training for Youth at Risk of Psychosis

Condition:   At Risk of Psychosis
Interventions:   Behavioral: Cognitive behavioral social skills;   Behavioral: Psychoeducation
Sponsors:   University of Calgary;   The Zucker Hillside Hospital;   University of California, San Diego
Recruiting - verified August 2016

Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis

Condition:   Attenuated Psychosis Syndrome
Interventions:   Behavioral: Exercise 1;   Behavioral: Exercise 2
Sponsors:   University of Colorado, Boulder;   University of Colorado, Denver;   National Institute of Mental Health (NIMH);   Northwestern University
Recruiting - verified October 2016

Culturally Adapted Cognitive Behavior Therapy for Psychosis in Pakistan

Condition:   Psychosis
Intervention:   Behavioral: Culturally Adapted Cognitive behavior therapy
Sponsors:   Pakistan Institute of Learning and Living;   University of Manchester;   Dow University of Health Sciences;   Abbasi Shaheed Hospital
Completed - verified July 2014

Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis

Condition:   Clinical High Risk for Psychosis
Interventions:   Drug: Aspirin;   Drug: Placebo
Sponsor:   Yale University
Recruiting - verified July 2016

A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

Condition:   Alzheimer's Disease Psychosis
Interventions:   Drug: Pimavanserin tartrate;   Drug: Placebo
Sponsor:   ACADIA Pharmaceuticals Inc.
Active, not recruiting - verified July 2016

Cognitive Remediation for First Episode of Psychosis Patients

Condition:   Psychosis
Interventions:   Behavioral: Cognitive remediation;   Behavioral: Social cognition training
Sponsor:   University of Manchester
Active, not recruiting - verified July 2016

Ziprasidone in the Psychosis Prodrome

Condition:   Psychosis Prodrome
Interventions:   Drug: ziprasidone;   Drug: placebo
Sponsor:   Yale University
Completed - verified September 2016

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Condition:   Parkinson's Disease Psychosis
Intervention:   Drug: Pimavanserin tartrate (ACP-103)
Sponsor:   ACADIA Pharmaceuticals Inc.
Active, not recruiting - verified April 2017

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Condition:   Parkinson's Disease Psychosis
Interventions:   Drug: Pimavanserin tartrate (ACP-103);   Drug: Pimavanserin tartrate (ACP-103);   Drug: Placebo
Sponsor:   ACADIA Pharmaceuticals Inc.
Completed - verified April 2017

Refine Your Search Advanced Search